How Peptides Are Taken: The Forms That Exist
Pens, powders, capsules, sprays, creams, infusions — a descriptive map of the forms peptides come in. Deliberately no instructions: for anything hands-on, the route is a licensed clinician.
Ask how a peptide is “taken” and you get a dozen different answers, because the honest answer is: it depends which world the product comes from. An approved drug, a compounded prescription, and a gray-market powder with the same molecule’s name on the label arrive in different forms, through different channels, with different oversight. This page maps the forms that exist in the world — descriptively, the way our Legal Mandate requires.
What this page deliberately does not contain: instructions. No technique, no amounts, no mixing ratios, no schedules — nothing that walks a person through using any product. That is not a gap in our research; it is the line this site exists to hold. If you are looking for hands-on guidance about a specific product, the route is a licensed clinician who can examine you and prescribe legally — start with the doctors directory. If you have a question about the landscape, ask us and we will answer it in print.
The forms
Freeze-dried powder in a vial. The default form of the research and gray-market world, and common in compounding: the peptide is freeze-dried (lyophilized) into a powder cake or dust at the bottom of a sealed vial, because peptides keep longer dry than dissolved. In clinical and laboratory settings, such powder is returned to liquid form before use — a step the industry calls reconstitution. How that is done for any given product is precisely the kind of operational detail this page does not publish; it belongs to pharmacists and prescribing clinicians, and the documented record of what happens when it is improvised — contamination, wrong contents, endotoxin — is on our dangers pages.
Manufacturer-filled pens and pre-mixed products. The approved-drug world: GLP-1 medicines such as semaglutide and tirzepatide reach patients as factory-filled injector pens and cartridges, manufactured under pharmaceutical quality systems, dispensed by pharmacies against prescriptions. Same broad technology — a peptide in solution — inside an entirely different chain of custody. The gap between this form and a powder vial is most of what our manufacturing explainer is about.
Injection under the skin, or into muscle. Most injectable peptides in clinical discussion are given subcutaneously (into the fatty layer beneath the skin) or, less commonly, intramuscularly (into a muscle). These are routes of administration — categories, not instructions — and which route belongs to which product is a prescribing decision, made by clinicians for approved and compounded products every day. Nothing about a route makes an unapproved product approved.
Oral — capsules and tablets. The contested frontier. Most peptides are broken down by digestion, which is why so few exist in pill form — and why the exceptions are famous. The approved GLP-1 world has an oral formulation built on absorption-enhancing chemistry. In the gray-market world, oral versions of gut-associated peptides (BPC-157 is the standing example) are marketed on the argument that a molecule native to the stomach survives it — an argument our compound pages present as what it is: claimed by sellers and some clinicians, disputed by others, and untested in proper human trials either way.
Under the tongue (sublingual). Drops and dissolving tablets placed under the tongue, marketed on the theory that absorption through the oral mucosa bypasses digestion. Several gray-market and compounded products are sold in this form; the evidence base for the theory, compound by compound, is thin to absent.
Nasal sprays. Peptides discussed for brain and mood effects (semax and selank are the usual names) are commonly sold as nasal sprays, on the theory of nose-to-brain pathways. This is the form in one of the first-person harm accounts published by KFF Health News in October 2026 — months of fatigue, anxiety and twitching reported after a nasal BPC-157 product, causality unverified — which is why form is not a safety feature.
Topical — creams, gels, serums. The cosmetics lane: GHK-Cu is the headline molecule, sold in skin and hair products that sit in the cosmetics regulatory category rather than the drug category. Topical forms are also marketed for wound and scar contexts. A cream is not a loophole in drug law — claims determine category — but it is a different risk world from injection, and the site’s labels keep the lanes separate.
Clinic infusions (IV). Some peptides and peptide-adjacent compounds, NAD+ being the prominent example, are administered intravenously in clinic settings over extended sessions, under staff supervision. Clinic administration is a form, not a guarantee: the documented record includes an FDA Class I recall of clinic-channel NAD+ injections for endotoxin contamination (October 2025) and a CDC-reported outbreak tied to injectable glutathione at wellness clinics. Supervision changes the risk; it does not erase it.
Why the form matters more than the name
Two products can share a molecule’s name and share almost nothing else: different form, different purity, different sterility, different legal status, different evidence. That is why this site organizes its library by compound and keeps the labels on — seller, clinic, official, critic — and why “which peptide?” is only the second question. The first is: which world did this product come from, and what proof came with it?
For the personal version of any of these questions — what applies to you — the answer is a licensed clinician, in person, with your history in front of them: the doctors directory. For the educational version, ask us a question and the answer becomes a page everyone can read.
Educational information only — not medical advice. This page describes forms of administration that exist in the world; it is not a guide to using any product. Status as of November 9, 2026. See Our Legal Mandate.